English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This study was designed to evaluate MEK5 and ERK5 expression in colon cancer progression and to ascertain the relevance of MEK5/ERK5 signalling in colon cancer. Expression of MEK5 and ERK5 was evaluated in 323 human colon cancer samples. To evaluate the role of MEK5/ERK5 signalling in colon cancer, we developed a stable cell line model with differential MEK5/ERK5 activation. Impact of differential MEK5/ERK5 signalling was evaluated on cell cycle progression by flow cytometry and cell migration was evaluated by wound healing and transwell migration assays. Finally, we used an orthotopic xenograft mouse model of colon cancer to assess tumour growth and progression. Our results demonstrated that MEK5 and ERK5 are overexpressed in human adenomas ( P <0.01) and adenocarcinomas ( P <0.05), where increased ERK5 expression correlated with the acquisition of more invasive and metastatic potential ( P <0.05). Interestingly, we observed a significant correlation between ERK5 expression and NF- κ B activation in human adenocarcinomas ( P <0.001). We also showed that ERK5 overactivation significantly accelerated cell cycle progression ( P <0.05) and increased cell migration ( P <0.01). Furthermore, cells with overactivated ERK5 displayed increased NF- κ B nuclear translocation and transcriptional activity ( P <0.05), together with increased expression of the mesenchymal marker vimentin ( P <0.05). We further demonstrated that increased NF- κ B activation was associated with increased I κ B phosphorylation and degradation ( P <0.05). Finally, in the mouse model, lymph node metastasis was exclusively seen in orthotopically implanted tumours with overactivated MEK5/ERK5, and not in tumours with inhibited MEK5/ERK5. Our results suggested that MEK5/ERK5/NF- κ B signalling pathway is important for tumour onset, progression and metastasis, possibly representing a novel relevant therapeutic target in colon cancer treatment.

Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation